ClearPoint Neuro Balance Sheet Health
Financial Health criteria checks 6/6
ClearPoint Neuro has a total shareholder equity of $21.2M and total debt of $9.9M, which brings its debt-to-equity ratio to 47%. Its total assets and total liabilities are $42.7M and $21.5M respectively.
Key information
47.0%
Debt to equity ratio
US$9.95m
Debt
| Interest coverage ratio | n/a |
| Cash | US$23.14m |
| Equity | US$21.17m |
| Total liabilities | US$21.49m |
| Total assets | US$42.66m |
Recent financial health updates
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Dec 06
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Aug 18Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Jan 03ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Aug 18Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Apr 25ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Jan 19Recent updates
ClearPoint Neuro: Macro-Induced Multiple Compression
Apr 25Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Apr 19Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Mar 15Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?
Jan 04Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Dec 06Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?
Nov 06Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Aug 18ClearPoint Neuro, Inc. (NASDAQ:CLPT) Looks Just Right With A 40% Price Jump
Apr 17Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
Jan 03ClearPoint Neuro: Continuous Great Execution
Sep 19ClearPoint Neuro: Picks & Shovels Galore
Aug 19ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Aug 18ClearPoint Neuro: A 'Picks And Shovels' Biotech Company
Jul 25ClearPoint Neuro: Continuous Execution Despite Covid Headwind
May 20Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
Apr 25ClearPoint Neuro: A Strong Recovery Play Once COVID Subsides
Mar 18ClearPoint Neuro (NASDAQ:CLPT) Has Debt But No Earnings; Should You Worry?
Jan 19ClearPoint Neuro: Underlying Growth Potential Concealed By COVID
Jan 14ClearPoint Neuro: Becoming The Neurosurgical Platform Of Choice
Oct 01ClearPoint Neuro: Path To Being The Neurological Navigation Platform Company
Aug 06Health Check: How Prudently Does ClearPoint Neuro (NASDAQ:CLPT) Use Debt?
Jul 19Clearpoint Neuro (CLPT) Investor Presentation - Slideshow
May 28Why We Think Shareholders May Be Considering Bumping Up ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) CEO Compensation
May 27US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results
May 13ClearPoint Neuro partners with D&K Engineering
May 10ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Path To Profitability
Apr 16Financial Position Analysis
Short Term Liabilities: CLPT's short term assets ($36.2M) exceed its short term liabilities ($7.4M).
Long Term Liabilities: CLPT's short term assets ($36.2M) exceed its long term liabilities ($14.1M).
Debt to Equity History and Analysis
Debt Level: CLPT has more cash than its total debt.
Reducing Debt: CLPT's debt to equity ratio has reduced from 230.4% to 47% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CLPT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CLPT has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 27.1% each year.